Fri, Jul 25, 2014, 8:11 AM EDT - U.S. Markets open in 1 hr 19 mins

Recent

% | $
Click the to save as a favorite.

Durata Therapeutics, Inc. (DRTX) Message Board

  • rn_cde rn_cde May 29, 2014 9:35 AM Flag

    Another Upgrade folks!

    BofA/Merrill Lynch analyst Steve Byrne bumped his price target on Buy-rated Durata Therapeutics (NASDAQ: DRTX) to $22.00 (from $20.00) following recent FDA approval for Dalvance.

    Byrne said while approval was expected the risk adjustment revisions to their model increased its DCF-derived PO to $22 from $20.

    The analyst notes that shares are down 12% since the approval news, which they see as a particularly good buying opportunity.

    For an analyst ratings summary and ratings history on Durata Therapeutics click here. For more ratings news on Durata Therapeutics click here.
    Shares of Durata Therapeutics closed at $14.86 yesterday.

    Sentiment: Strong Buy

 
DRTX
13.94-0.39(-2.72%)Jul 24 3:59 PMEDT

Trending Tickers

i
Trending Tickers features significant U.S. stocks showing the most dramatic increase in user interest in Yahoo Finance in the previous hour over historic norms. The list is limited to those equities which trade at least 100,000 shares on an average day and have a market cap of more than $300 million.